{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_003",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:9565af6fb52b4d396dbeffab2537c060dedc67e7ef3139a2c047fe6e405e0b98",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:05.086249",
  "content": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 67\n- Active: 67\n- Screen Failures Cumulative: 5\n- Withdrawals Cumulative: 0\n\n### Enrollment By Dose Group\n- Low Dose: 18\n- Mid Dose: 17\n- High Dose: 16\n- Placebo: 16\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 24.8\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 14.9\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 38.8\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 65.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 45.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 11.9\n- Mid Dose\n  - IgG Titer (GMU) Mean: 48.1\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 24.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 72.3\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 106.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 77.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 14.5\n- High Dose\n  - IgG Titer (GMU) Mean: 63.5\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 30.5\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 95.5\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 152.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 108.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 29.4\n- Placebo\n  - IgG Titer (GMU) Mean: 10.7\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 2.9\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 4.6\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 5.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 7.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 6.9\n\n### Injection Site Reactions\n- Pain Percentage: 51.7\n- Erythema Percentage: 14.6\n- Swelling Percentage: 7.8\n- Induration Percentage: 10.0\n- Mean Pain Duration (Hours): 25.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 18.2\n- Fatigue Percentage: 32.7\n- Myalgia Percentage: 25.9\n- Headache Percentage: 17.3\n- Chills Percentage: 14.8\n\n### Safety Labs\n- WBC (K) Mean: 8.9\n- WBC (K) SD: 1.9\n- Lymphocyte Percentage Mean: 28.7\n- Lymphocyte Percentage SD: 6.8\n- Neutrophil Percentage Mean: 62.2\n- Neutrophil Percentage SD: 6.2\n- Platelets (K) Mean: 216\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 6.3\n- CRP (mg/L) SD: 1.9\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.3\n\n### Adverse Events\n- AE ID: VI-AE-0303, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-0346, Description: fever, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-0386, Description: injection site pain, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- Serum sample aliquoting completed for 25 subjects\n- Serum sample aliquoting completed for 19 subjects\n\n### Notes\n- Week 3: Immunogenicity assessments on schedule. 67 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 3,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}